Press releases & news
2cureX launches its first two IndiTreat® products CE-marked under the new IVD RegulationRead more
2cureX publishes interim report for Q2 2023Read more
Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET)Read more
2cureX Newsletter. Our colorectal cancer portfolio is on track – Pancreatic cancer is next.Read more
Share InformationSee our latest share information
Calendar & upcoming events
Commentary on Q2 2023 report – Infront Direkt Studios will host an interview with CEO Fernando Andreu regarding the results presented in the Q2 2023 report.Watch webcast
2cureX Webcast – Get the latest news from the second quarter of 2023 and Q&A with the Management of 2cureX.Watch webcast
All things permitting, we look forward to seeing you all at ESMO GI again this summer. We will be there in Barcelona in person from 28 June – 1 July. More details to follow.Go to event
Commentary on Q1 2023 report – Infront Direkt Studios will host an interview with CEO Fernando Andreu regarding the results presented in the Q1 2023 report.Watch webcast
STAY UPDATED WITH OUR NEWS AND PRESS RELEASES
Get notified by mail when news or press releases are published on our website.
In this latest blog, Fernando Andreu talks about the exciting expansion of the IndiTreat® product family to include a functional drug sensitivity test for pancreatic cancer in the near future.
Subscribe to our newsletter above.More
Information for Oncologists and Pathologists
Know more when it matters most:
With our IndiTreat® tests you can finally obtain personalised information, even on the classic compounds for the main chemotherapy backbone for your stage IV mCRC patients.
Information for Patients
You’ve been diagnosed with colorectal cancer, and it is in stage IV. There are rational treatment choices to be made. Which therapy is more likely to impact the tumor? Ask your doctor about IndiTreat®.More